BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LGR, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD. cis -4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3- h ]quinazolin-2-amine (A-987306), A New Histamine H 4 R Antagonist that Blocks Pain Responses against Carrageenan-Induced Hyperalgesia. J Med Chem 2008;51:7094-8. [DOI: 10.1021/jm8007618] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Leurs R, Vischer HF, Wijtmans M, de Esch IJ. En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends in Pharmacological Sciences 2011;32:250-7. [DOI: 10.1016/j.tips.2011.02.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
2 Thurmond RL. The histamine H4 receptor: from orphan to the clinic. Front Pharmacol 2015;6:65. [PMID: 25873897 DOI: 10.3389/fphar.2015.00065] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 11.9] [Reference Citation Analysis]
3 Sengmany S, Le Gall E, Léonel E. An electrochemical synthesis of functionalized arylpyrimidines from 4-amino-6-chloropyrimidines and aryl halides. Molecules 2011;16:5550-60. [PMID: 21716176 DOI: 10.3390/molecules16075550] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
4 Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP. Clinical Development of Histamine H4 Receptor Antagonists. Handb Exp Pharmacol 2017;241:301-20. [PMID: 28233185 DOI: 10.1007/164_2016_130] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
5 Tatarkiewicz J, Rzodkiewicz P, Żochowska M, Staniszewska A, Bujalska-Zadrożny M. New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders. Arch Med Sci 2019;15:537-53. [PMID: 30899308 DOI: 10.5114/aoms.2017.68534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sander K, Kottke T, Tanrikulu Y, Proschak E, Weizel L, Schneider EH, Seifert R, Schneider G, Stark H. 2,4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization. Bioorganic & Medicinal Chemistry 2009;17:7186-96. [DOI: 10.1016/j.bmc.2009.08.059] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
7 Lane CA, Hay D, Mowbray CE, Paradowski M, Selby MD, Swain NA, Williams DH. Synthesis of novel histamine H4 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2012;22:1156-9. [DOI: 10.1016/j.bmcl.2011.11.098] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
8 Tiligada E, Zampeli E, Sander K, Stark H. Histamine H 3 and H 4 receptors as novel drug targets. Expert Opinion on Investigational Drugs 2009;18:1519-31. [DOI: 10.1517/14728220903188438] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 7.8] [Reference Citation Analysis]
9 Wolińska R, Leśniak A, Żochowska M, Sacharczuk M, Kieć-kononowicz K, Bujalska-zadrożny M. Antinociceptive effect of co-administered NMDA and histamine H4 receptor antagonists in a rat model of acute pain. Pharmacological Reports 2017;69:222-8. [DOI: 10.1016/j.pharep.2016.10.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol 2010;161:755-67. [PMID: 20636392 DOI: 10.1111/j.1476-5381.2010.00961.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 8.8] [Reference Citation Analysis]
11 Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev 2015;67:601-55. [PMID: 26084539 DOI: 10.1124/pr.114.010249] [Cited by in Crossref: 263] [Cited by in F6Publishing: 240] [Article Influence: 43.8] [Reference Citation Analysis]
12 Hammer SG, Gobleder S, Naporra F, Wittmann HJ, Elz S, Heinrich MR, Strasser A. 2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity. Bioorg Med Chem Lett 2016;26:292-300. [PMID: 26718844 DOI: 10.1016/j.bmcl.2015.12.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
13 Lal S, Chowdhury A, Namboothiri IN. Synthesis of annulated oxa-triquinanes and oxa-diquinanes via cascade Michael addition-intramolecular alkylation involving α-halodicyclopentadienones. Tetrahedron 2017;73:1297-305. [DOI: 10.1016/j.tet.2017.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
14 Beaton G, Moree WJ. The expanding role of H 1 antihistamines: a patent survey of selective and dual activity compounds 2005 – 2010. Expert Opinion on Therapeutic Patents 2010;20:1197-218. [DOI: 10.1517/13543776.2010.510516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
15 Corrêa MF, dos Santos Fernandes JP. Histamine H4 receptor ligands: future applications and state of art. Chem Biol Drug Des 2015;85:461-80. [PMID: 25228262 DOI: 10.1111/cbdd.12431] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
16 Seeger C, Christopeit T, Fuchs K, Grote K, Sieghart W, Danielson UH. Histaminergic pharmacology of homo-oligomeric β3 γ-aminobutyric acid type A receptors characterized by surface plasmon resonance biosensor technology. Biochemical Pharmacology 2012;84:341-51. [DOI: 10.1016/j.bcp.2012.04.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
17 Pappalardo M, Shachaf N, Basile L, Milardi D, Zeidan M, Raiyn J, Guccione S, Rayan A. Sequential application of ligand and structure based modeling approaches to index chemicals for their hH4R antagonism. PLoS One 2014;9:e109340. [PMID: 25330207 DOI: 10.1371/journal.pone.0109340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zak A, Lemaire L, Chalon S, Chicheri G, Marzag H, Bodard S, Sérrière S, Routier S, Buron F, Vercouillie J. [18 F]-labeled positron emission tomography ligand for the histamine H4 receptor. J Labelled Comp Radiopharm 2021;64:363-72. [PMID: 34089268 DOI: 10.1002/jlcr.3929] [Reference Citation Analysis]
19 Savall BM, Gomez L, Chavez F, Curtis M, Meduna SP, Kearney A, Dunford P, Cowden J, Thurmond RL, Grice C, Edwards JP. Tricyclic aminopyrimidine histamine H4 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2011;21:6577-81. [DOI: 10.1016/j.bmcl.2011.08.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
20 Savall BM, Edwards JP, Venable JD, Buzard DJ, Thurmond R, Hack M, Mcgovern P. Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands. Bioorganic & Medicinal Chemistry Letters 2010;20:3367-71. [DOI: 10.1016/j.bmcl.2010.04.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
21 Verheij MH, de Graaf C, de Kloe GE, Nijmeijer S, Vischer HF, Smits RA, Zuiderveld OP, Hulscher S, Silvestri L, Thompson AJ, van Muijlwijk-Koezen JE, Lummis SC, Leurs R, de Esch IJ. Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H₄ and the ion channel serotonin 5-HT₃A. Bioorg Med Chem Lett 2011;21:5460-4. [PMID: 21782429 DOI: 10.1016/j.bmcl.2011.06.123] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
22 Strasser A. Molecular modeling and QSAR-based design of histamine receptor ligands. Expert Opinion on Drug Discovery 2009;4:1061-75. [DOI: 10.1517/17460440903264972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
23 Marson CM. Targeting the Histamine H 4 Receptor. Chem Rev 2011;111:7121-56. [DOI: 10.1021/cr900166w] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
24 Yu F, Bonaventure P, Thurmond RL. The Future Antihistamines: Histamine H3 and H4 Receptor Ligands. In: Thurmond RL, editor. Histamine in Inflammation. Boston: Springer US; 2010. pp. 125-40. [DOI: 10.1007/978-1-4419-8056-4_12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
25 Smits RA, Lim HD, van der Meer T, Kuhne S, Bessembinder K, Zuiderveld OP, Wijtmans M, de Esch IJ, Leurs R. Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics. Bioorganic & Medicinal Chemistry Letters 2012;22:461-7. [DOI: 10.1016/j.bmcl.2011.10.104] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
26 Kiss R, Keseru˝ GM. Histamine H4 receptor ligands and their potential therapeutic applications. Expert Opinion on Therapeutic Patents 2009;19:119-35. [DOI: 10.1517/13543770802691085] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
27 Nordemann U, Wifling D, Schnell D, Bernhardt G, Stark H, Seifert R, Buschauer A. Luciferase reporter gene assay on human, murine and rat histamine H4 receptor orthologs: correlations and discrepancies between distal and proximal readouts. PLoS One 2013;8:e73961. [PMID: 24023919 DOI: 10.1371/journal.pone.0073961] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
28 Nijmeijer S, Vischer HF, Rosethorne EM, Charlton SJ, Leurs R. Analysis of Multiple Histamine H 4 Receptor Compound Classes Uncovers Gα i Protein- and β-Arrestin2-Biased Ligands. Mol Pharmacol 2012;82:1174-82. [DOI: 10.1124/mol.112.080911] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
29 Seifert R, Strasser A, Schneider EH, Neumann D, Dove S, Buschauer A. Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci 2013;34:33-58. [PMID: 23254267 DOI: 10.1016/j.tips.2012.11.001] [Cited by in Crossref: 118] [Cited by in F6Publishing: 103] [Article Influence: 11.8] [Reference Citation Analysis]
30 Koenig JR, Liu H, Drizin I, Witte DG, Carr TL, Manelli AM, Milicic I, Strakhova MI, Miller TR, Esbenshade TA, Brioni JD, Cowart M. Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: Effects of substitution about the rigidifying ring. Bioorganic & Medicinal Chemistry Letters 2010;20:1900-4. [DOI: 10.1016/j.bmcl.2010.01.131] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
31 Leurs R, Chazot PL, Shenton FC, Lim HD, de Esch IJ. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol. 2009;157:14-23. [PMID: 19413568 DOI: 10.1111/j.1476-5381.2009.00250.x] [Cited by in Crossref: 107] [Cited by in F6Publishing: 89] [Article Influence: 8.2] [Reference Citation Analysis]
32 Strakhova MI, Cuff CA, Manelli AM, Carr TL, Witte DG, Baranowski JL, Vortherms TA, Miller TR, Rundell L, McPherson MJ, Adair RM, Brito AA, Bettencourt BM, Yao BB, Wetter JM, Marsh KC, Liu H, Cowart MD, Brioni JD, Esbenshade TA. In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties. Br J Pharmacol 2009;157:44-54. [PMID: 19413570 DOI: 10.1111/j.1476-5381.2009.00236.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
33 Wagner E, Wittmann H, Elz S, Strasser A. Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor—H1/H4 receptor selectivity. Naunyn-Schmiedeberg's Arch Pharmacol 2014;387:235-50. [DOI: 10.1007/s00210-013-0926-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
34 Krautscheid Y, Senning CJ, Sartori SB, Singewald N, Schuster D, Stuppner H. Pharmacophore modeling, virtual screening, and in vitro testing reveal haloperidol, eprazinone, and fenbutrazate as neurokinin receptors ligands. J Chem Inf Model 2014;54:1747-57. [PMID: 24849814 DOI: 10.1021/ci500106z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
35 Nagarajan G, Mariappanadar V, Tamizh M, Kaliappan I, Elden BT. Effect of H4R antagonist N -(2-aminoethyl)-5-chloro-1 H -indol-2-carboxamides and 5-chloro-2-(piperazin-1-ylmethyl)-1 H -benzimidazole on histamine and 4-methylhistamine-induced mast cell response. Journal of Receptors and Signal Transduction 2017;37:304-13. [DOI: 10.1080/10799893.2016.1247863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]